Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy.

Background

The development of polyclonal nephelometric immunoassays for the measurement of free immunoglobulin light chains (FLC) in the serum has changed screening algorithms, classifications and the monitoring of a number of plasma cell dyscrasias [ 1 - 3 ]. These assays, which utilise latex-conjugated polyclonal antisera, when combined with serum protein electrophoresis provide a sensitive screening tool for plasma cell dyscrasias. Together they identify all cases of multiple myeloma, 96% of AL-amyloidosis and 85% of monoclonal gammopathy of undetermined significance (MGUS) [ 4 ]. These FLC assays have a particular role for the diagnosis and monitoring of light chain only multiple myeloma [ 1 ], but in addition their sensitivity has lead to the development of a new classification of response of multiple myeloma: stringent complete response (when the FLC ratio has normalised, in addition to standard parameters). Furthermore the assessment of serum FLC provides an additional tool for the risk stratification of MGUS [ 5 ] and asymptomatic myeloma [ 6 ] and has allowed the description of a new class of FLC only MGUS [ 7 ].

Monoclonal serum FLC exhibit different inter-patient [ 8 ] and intra-patient [ 9 ] physio-chemical properties. This may reflect the genetic [ 10 ] and biological diversity of the FLC’s and contribute to one of the most significant complications of monoclonal FLC, acute kidney injury (AKI) secondary to cast nephropathy; when severe this has a profound impact on morbidity and mortality and reduces quality of life. The rapid diagnosis of AKI due to myeloma cast nephropathy facilitated by monoclonal FLC, allows the rapid initiation of disease specific treatment [ 11 ]. Recent work has demonstrated that when treatments are targeted to provide a rapid reduction in circulating concentrations of monoclonal FLC renal recovery occurs in the majority of patients [ 12 - 15 ].

Recently, new immunoassays which use monoclonal antibodies against FLC have become commercially available. The purpose of this study was to compare the diagnostic sensitivity of these new monoclonal assays with the established polyclonal FLC assays in the context of individuals presenting with new severe AKI secondary to multiple myeloma where there is a clear need for a rapid diagnosis.

Results and discussion

The purpose of this study was to compare the diagnostic sensitivity of the two commercially available immunoassays for the identification of monoclonal FLC, in patients with severe AKI and multiple myeloma. Similar reference range comparisons between the two assays had previously been reported [ 16 ], therefore for these assays to be used interchangeably it is appropriate to utilise clinical cut-offs identified by the predicate assays. Sera from 30 patients with severe AKI and multiple myeloma were available for analysis. Patients had a median age of 68.5 years and 70% were male. Seventeen patients had a monoclonal λ FLC, 11 patients had a monoclonal κ FLC and two patients had no demonstrable monoclonal FLC (Table). The renal diagnoses in the two patients without a monoclonal FLC were acute tubular necrosis in the context of severe infection and obstructive nephropathy, respectively. In the remaining 28 patients the cause of the AKI was attributed to multiple myeloma and a nephrotoxic FLC (Figure 1 A).

The established FLC assays, which utilise polyclonal antibodies, have high rates of diagnostic sensitivity in patients with myeloma kidney [ 11 ], multiple myeloma, AL-amyloidosis and MGUS [ 17 ]. In this first clinical comparison of the established assays with the new assays, which use monoclonal antibodies, we found one of the seventeen patients (6%) with a monoclonal λ FLC was miss-classified by the assay (Tables 1 and 2 ). The patient and 7, had 1810 mg/L of λ FLC with the historic assays and 1 mg/L λ FLC / 4 mg/L κ FLC by the new assay incorrectly indicating a kappa clone, in accordance with manufacturers instructions antigen excess checks were not performed. All patients with a monoclonal κ FLC were identified with the new assay. The missed case of λ FLC monoclonality indicates the limitation of using monoclonal antibodies, as they have a limited number of epitopes which they can identify; the myriad structural variations in monoclonal FLC means that there will be cases where a monoclonal antibody based assay will not detect FLC clonality; this case is a practical demonstration of this principle.

The correlation coefficient of the two FLC assays was less good for patients with monoclonal λ FLC (Figure 1 B) than for patients with monoclonal κ FLC (Figure 1 C): r = 0.617, p < 0.003 and r = 0.843, p = 0.001 respectively. The correlation of the FLC ratios between the two assays was 0.894, P < 0.01. The shortfalls in correlations of the absolute values of FLC are relevant for both the diagnosis and monitoring of patients. First, five of the 28 patients (18%) with AKI secondary to multiple myeloma were misclassified by the new assays as having FLC levels below the nephrotoxic threshold of 500 mg/L, four of these patients had a monoclonal λ FLC and one had a monoclonal κ FLC. Second, disease response as defined by the reduction in serum FLC levels is increasing in importance in all patients with multiple myeloma, but has particularly relevance in those with AKI where an early reduction in monoclonal FLC both guides treatment and suggests outcome [ 12 - 15 ]. It is imperative therefore that the established ‘risk’ and ‘response’ levels of the original FLC assays cannot be used for the new FLC assays. Rather levels specific for the new assays should now be identified. Clinicians will then need to be made aware of these new levels and informed which assay their laboratory is using.

The principal limitation of this work is the small population size. Further work should now be undertaken to assess these new monoclonal assays in larger populations and specific disease groups such as AL-amyloid, where the potentially inferior performance of the new λ assay may be of particular importance. In addition, the correlations between these assays are not robust enough to apply the current definitions of myeloma response based on FLC monoclonality from the new assays.

Conclusion

This study highlights the importance of large comparative studies of new immunoassays before they are used in clinical practice. This provisional work demonstrated that the new monoclonal N-latex assay for FLC measurement did not robustly replicate the results of the established polyclonal FLC assays. Further work is now required before these new assays can be adopted into clinical practice.

Methods

This study was undertaken as a service evaluation at the University Hospital Birmingham. All data analysis was coded and anonymised. Sera from patients, who presented with new dialysis dependent renal failure, to the renal unit at the University Hospital Birmingham, were screened for inclusion in a trial assessing the management of severe renal failure in multiple myeloma (COREC 05/Q2706/107, South Birmingham Research Ethics Committee), results of which have been reported previously [ 14 , 18 , 19 ].

Study populations

Dialysis-dependent renal failure was defined as an estimated GFR of <15mls/min/1.73 m 2 , as calculated by the abbreviated MDRD equation and a clinical or metabolic requirement for dialysis as identified by the reviewing nephrologist [ 20 ]. Attribution of the cause of renal failure to multiple myeloma was based on renal histology or in cases where a renal biopsy was contraindicated when all other potential causes were excluded. The clinical diagnosis of multiple myeloma was made by a consultant haematologist in accordance with international diagnostic criteria [ 21 ].

Laboratory and statistical analysis

Serum samples were stored at −80°C until thawed for the current study; previous work has demonstrated the stability of FLC concentrations in urine samples over many years [ 22 ] and apparent stability in serum samples [ 17 ]. Serum κ and λ FLC concentrations were measured by nephelometry, on a Dade-Behring BN™II Analyser, using particle-enhanced, high-specificity, homogeneous immunoassays (Freelite™, The Binding Site Group Ltd, Birmingham, UK [ 23 ] and N-Latex FLC, Siemens Healthcare Diagnostic Products GmBh, Germany). FLC results were compared with the published reference range for the FLC ratio in patients with renal failure reference range (0.37-3.17) [ 24 ].

Data were analysed using SPSS 17.0 for Windows. Spearman’s correlation coefficient was used to assess the correlation of results between the two assays and Chi square test to assess the classification of the patients by the two assays.

Competing interests

CH and PC have received research funding from the Binding Site, CH is a consultant to the Binding Site.

Authors’ contributions

All authors were involved in the study design and manuscript preparation. CH undertook the data analysis. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6890/12/12/prepub

Dispenzieri A Kyle R Merlini G International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Leukemia 2009 23 215 224 10.1038/leu.2008.307 19020545

Kyle RA Durie BG Rajkumar SV Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Leukemia 2010 24 1121 1127 10.1038/leu.2010.60 20410922 PMC7020664

Blade J Dimopoulos M Rosinol L Rajkumar SV Kyle RA Smoldering (asymptomatic) multiple myeloma: Current diagnostic criteria, new predictors of outcome, and follow-up recommendations J Clin Oncol 2010 28 690 697 10.1200/JCO.2009.22.2257 20026810 PMC2816002

Katzmann JA Kyle RA Benson J Screening panels for detection of monoclonal gammopathies Clin Chem 2005 55 1517 1522 19520758 10.1373/clinchem.2009.126664 PMC3773468

Rajkumar SV Kyle RA Therneau TM Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undermined significance Blood 2005 106 812 817 10.1182/blood-2005-03-1038 15855274 PMC1895159

Dispenzieri A Kyle RA Katzmann JA Immunoglobulin free light chain ratio is an independent risk factor of progression of smoldering (asymptomatic) multiple myeloma Blood 2008 111 785 789 10.1182/blood-2007-08-108357 17942755 PMC2200851

Dispenzieri A Katzmann JA Kyle RA Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population based cohort study Lancet 2010 375 1721 1728 10.1016/S0140-6736(10)60482-5 20472173 PMC2904571

Bourne PC Ramsland PA Shan L Three-dimensional structure of an immunoglobulin light chain dimer with amyoidogenic properties Acta Crystallogr D: Biol Crystallogr 2002 D58 815 823 11976493 10.1107/s0907444902004183

Harding S Provot F Beuscart J-B Cook M Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis Nephrol Dial Transplant 2011 26 1438 1441 10.1093/ndt/gfr019 21406545

Sanders PW Booker BB Pathobiology of cast nephropathy from human Bence Jones proteins J Clin Invest 1992 89 630 639 10.1172/JCI115629 1737851 PMC442896

Hutchison CA Plant T Drayson M Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure BMC Nephrol 2008 9 11 10.1186/1471-2369-9-11 18808676 PMC2564915

Hutchison CA Cockwell P Stringer S Early reduction of serum-free light chains associates with renal recovery in myeloma kidney J Am Soc Nephrol 2011 22 1129 1136 10.1681/ASN.2010080857 21511832 PMC3103732

Leung N Gertz MA Zeldenrust SR Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains Kidney Int 2008 73 1282 1288 10.1038/ki.2008.108 18385667

Hutchison CA Bradwell AR Cook M Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis Clin J Am Soc Nephrol 2009 4 745 754 10.2215/CJN.04590908 19339414 PMC2666427

Burnette BL Leung N Rajkumar SV Renal improvement in myeloma with bortezomib plus plasma exchange N Engl J Med 2011 364 1607 1616 10.1056/NEJMoa1100356 21675906

Velthuis TH Knop I Stam P N Latex FLC – new monoclonal high-performance assays for the determination of free light chain kappa and lambda Clin Chem Lab Med 2011 49 1323 1332 21663464 10.1515/CCLM.2011.624

Katzmann JA Clark RJ Abraham RS Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains Clin Chem 2002 48 1437 1444 12194920

Hutchison CA Cockwell P Reid S Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies J Am Soc Nephrol 2007 18 886 895 10.1681/ASN.2006080821 17229909

Hutchison CA Harding S Mead GP Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care Artif Organs 2008 32 910 917 10.1111/j.1525-1594.2008.00653.x 19133018

Vorvoort G Willems HL Wetzels JF Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: Validity of a new (MDRD) prediction equation Nephrol Dial Transplant 2002 17 1909 1913 10.1093/ndt/17.11.1909 12401845

Bird JM Owen RG D’Sa S Guidelines for the diagnosis and management of multiple myeloma 2011 Br J Haematol 2011 154 32 75 10.1111/j.1365-2141.2011.08573.x 21569004

Tencer J Thysell H Andersson K Grubb A Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at −20 degrees C Scand J Urol Nephrol 1997 31 67 71 10.3109/00365599709070305 9060087

Bradwell AR Carr-Smith HD Mead GP Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine Clin Chem 2001 47 673 680 11274017

Hutchison CA Harding S Hewins P Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease Clin J Am Soc Nephrol 2008 3 1684 1690 10.2215/CJN.02290508 18945993 PMC2572283